Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations, and lifted its full-year guidance as sales from the company's medtech business jumped.
That compares with a net income of $4.8 billion, or $1.80 per share, for the same period a year ago.
Excluding certain items, adjusted earnings per share were $2.80 for the period.
J&J is now forecasting full-year sales of $98.80 billion to $99.80 billion, about $1 billion higher than the guidance provided in April.
The company raised its 2023 adjusted earnings outlook to $10.70 to $10.80 per share, from a previous forecast of $10.60 to $10.70 per share.
Persons:
Johnson
Organizations:
UnitedHealth, Elevance, Refinitiv